Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography

Journal of Chromatography B: Biomedical Applications

Volumn 703, Issue 1-2, 1997, Pages 235-241

  Burger, D M ^a   De Graaff, M ^a   Wuis, E W ^a   Koopmans, P P ^a   Hekster, Y A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Enzyme inhibitors; Human immunodeficiency virus protease inhibitor; Indinavir

Indexed keywords

ACETONITRILE; DIDANOSINE; INDINAVIR; PROTEINASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETONITRILES; ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; DRUG STABILITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TIME FACTORS;

EID: 0031465289     PISSN: 15726495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4347(97)00421-0     Document Type: Article

References (3)

1. BHIVA Guidelines Co-ordinating Committee, Lancet, 349 (1997) 1086.
2. Woolf E., Au T., Haddix H., Matuszewski B. J. Chromatogr. A. 692:1995;45.
3. Crixivan Product Monograph, Merck and Co., Rahway, NJ, 1996.